Cellular Biomedicine Group Inc. Daily Stock Analysis

Daily Stock Analysis, CBMG, Cellular Biomedicine Group Inc, priceseries

Cellular Biomedicine Group Inc. Daily Stock Analysis
Stock Information
Open
17.65
Close
17.65
High
17.85
Low
17.40
Previous Close
17.65
Daily Price Gain
0.00
YTD High
22.75
YTD High Date
Jan 29, 2018
YTD Low
11.35
YTD Low Date
Jan 2, 2018
YTD Price Change
5.15
YTD Gain
41.20%
52 Week High
22.75
52 Week High Date
Jan 29, 2018
52 Week Low
5.50
52 Week Low Date
May 25, 2017
52 Week Price Change
11.55
52 Week Gain
189.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
7.35
Jul 10. 2017
8.59
14 Trading Days
16.87%
Link
LONG
Aug 28. 2017
9.00
Sep 15. 2017
10.47
13 Trading Days
16.38%
Link
LONG
Oct 30. 2017
9.80
Nov 8. 2017
10.41
7 Trading Days
6.22%
Link
LONG
Jan 2. 2018
12.50
Jan 23. 2018
18.50
14 Trading Days
48.00%
Link
Company Information
Stock Symbol
CBMG
Exchange
NasdaqGM
Company URL
http://www.cellbiomedgroup.com
Company Phone
(408) 973-7884
CEO
Bizuo Liu
Headquarters
California
Business Address
19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO, CA 95014
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001378624
About

Cellular Biomedicine Group, Inc. is a biopharmaceutical company. The company engages in the development of treatments for degenerative and cancerous diseases utilizing proprietary cell-based technologies. Its technology include immune cell therapy for treatment of a range of cancers using Chimeric Antigen Receptor T cell, cancer vaccine, and T Central Memory cell technology; and human adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. Cellular Biomedicine Group was founded in 2009 and is headquartered in Cupertino, CA.

Description

Cellular Biomedicine Group, Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. The company operates through two segments, Biomedicine and Consulting. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, spinal muscular atrophy, various inflammatory diseases, and joint degeneration and metabolic diseases. The company develops treatments utilizing proprietary cell technologies comprising tumor cell specific dendritic cells for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint disease; human umbilical cord-derived mesenchymal progenitor cells; human embryo-derived motor neuron progenitor precursor cells; and human embryo-derived neuronal progenitor precursor cells for the treatment of central nervous system diseases. It also provides consulting services to companies who seek access to the U.S. capital markets. The company is headquartered in Palo Alto, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading